Résumé
Approximately 80% of patients with hepatocellular carcinoma [HCC] are untreatable because of advanced tumor stages at presentation. Therefore, finding newer markers for screening and diagnosing HCC is of utmost importance. Clusterin [CLU] is a 449 amino acid, heterodimeric glycoprotein with a plausible role in the regeneration, migration, and anti-apoptosis of tumor cells. It has been implicated in many malignancies such as prostate and pancreatic adenocarcinomas, but its role in HCC is not well defined. We aimed to evaluate the diagnostic performance of serum CLU level in diagnosing HCC on top of hepatitis C virus-related liver cirrhosis, and comparing it to that of alpha fetoprotein [AFP]. Twenty cases of apparently healthy subjects, 27 cases of hepatitis C virus-related liver cirrhosis [CHC cases], and 44 HCC cases on top of hepatitis C virus-related liver cirrhosis were included in this study. Serum CLU concentration was determined using a quantitative sandwich enzyme immunoassay technique. Serum clusterin level showed a significant increase in the HCC group compared to the control group [151.96 +/- 32.74 vs. 111.40 +/- 27.46] and to the CI4t group [151.96 +/- 32.74 vs. 89.12 +/- 31.62], while a significant decrease in serum clusterin level was found in the CHC group compared to the control group [89.12 +/- 31.62 vs. 111.40 +/- 27.46]. Based on receiver operator